Naked DNA vaccines have shown promise for developing protective immunity by either T helper (Th)1 cell or Th2 cell-dependent responses. However, delivery has been primarily limited to peripheral sites rather than mucosal tissues. Consequently, minimal secretory (s)-IgA responses or immune mucosal Th cells are manifested. To successfully immunize the mucosa, efforts must consider the natural barriers at mucosal surfaces, and effectively target mucosal inductive tissues. In an effort to facilitate optimal mucosal immunity in the oral cavity, studies are proposed to utilize a DNA delivery system whereby the expression plasmid is complexed with a M cell-targeting molecule to ferry the DNA to mucosal inductive tissues following intranasal (i.n.) immunization. Much like live vector vaccine delivery systems which mediate host entry via M cells, it is hypothesized that the M cell ligand, reovirus protein sigma 1, will direct the DNA to the nasal-associated lymphoid tissue (NALT) and shared lymph nodes of the salivary-associated lymphoid tissues (SALT) for the appropriate stimulation of mucosal B and T cell subsets. Thus, the objective for this proposal is to test the effectiveness of this novel vaccine delivery system in promoting salivary s-IgA and IgG antibody responses. To further this effort, studies in Specific Aim 1 are focused in assessing the types and magnitude of mucosal antibody responses and the supportive CD4+ T cells induced following i.n. immunization with the protein sigma 1-directed DNA vaccine. Studies in Specific Aim 2 are focused on optimizing CTL responses by the SALT.
For Specific Aim 3, to circumvent the possibility of inducing neutralizing antibodies against protein sigma 1, the M cell lectin from Ulex europaeus, will be tested for its ability to ferry the DNA vaccine to mucosal inductive tissues to elicit antigen-specific salivary antibody responses as well as their supportive CD4+ T cells. The last set of studies to be conducted will assess whether the incorporation of GM-CSF or IL-18 cDNA to co-immunize mice with the vaccine cDNA will improve mucosal IgA responses and mucosal CTL responses. These studies will provide the basis for future development of subunit vaccines to target the NALT for eliciting protective immunity in the oral cavity and SALT.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE013812-02
Application #
6380005
Study Section
Oral Biology and Medicine Subcommittee 1 (OBM)
Program Officer
Shum, Lillian
Project Start
2000-09-01
Project End
2005-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
2
Fiscal Year
2001
Total Cost
$208,250
Indirect Cost
Name
Montana State University Bozeman
Department
Veterinary Sciences
Type
Schools of Earth Sciences/Natur
DUNS #
City
Bozeman
State
MT
Country
United States
Zip Code
59717
Suzuki, Hideaki; Sekine, Shinichi; Kataoka, Kosuke et al. (2008) Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells. Gastroenterology 135:917-25
Rynda, Agnieszka; Maddaloni, Massimo; Mierzejewska, Dagmara et al. (2008) Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. J Immunol 180:5187-200
Maddaloni, Massimo; Staats, Herman F; Mierzejewska, Dagmara et al. (2006) Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J Immunol 177:5524-32
Walters, Nancy; Trunkle, Theresa; Sura, Michael et al. (2005) Enhanced immunoglobulin A response and protection against Salmonella enterica serovar typhimurium in the absence of the substance P receptor. Infect Immun 73:317-24
Wang, Xinhai; Kochetkova, Irina; Haddad, Asmahan et al. (2005) Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope. Vaccine 23:3836-42
Pascual, David W (2004) The role of tachykinins on bacterial infections. Front Biosci 9:3209-17
Wang, Xinhai; Hillemeyer, Peter; Pascual, David W (2003) Segregation of mechanisms for cytotoxic T lymphocyte killing between lungs and regional lymph nodes subsequent to intratracheal delivery of adenovirus 2 vector. Viral Immunol 16:525-39
Csencsits, Keri L; Jutila, Mark A; Pascual, David W (2002) Mucosal addressin expression and binding-interactions with naive lymphocytes vary among the cranial, oral, and nasal-associated lymphoid tissues. Eur J Immunol 32:3029-39
Wu, Y; Wang, X; Csencsits, K L et al. (2001) M cell-targeted DNA vaccination. Proc Natl Acad Sci U S A 98:9318-23